Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Jumps Into Lucrative Adjuvant NSCLC Space With Keytruda Data

You may also be interested in...



BMS’s Revlimid Loss Of Exclusivity Is Not As Bad As Expected, But Not For Long

The company credited generics’ late market entry, but that benefit is not expected to last; the firm lowered guidance for annual sales of the oncologic.

BMS’s Revlimid Loss Of Exclusivity Is Not As Bad As Expected, But Not For Long

The company credited generics’ late market entry, but that benefit is not expected to last; the firm lowered guidance for annual sales of the oncologic. The firm stressed growth opportunities ahead for Opdivo, Opdualag and Camzyos.

Keytruda Adjuvant Kidney Cancer Data Cement The Future Of IO

The data illustrate the growing importance of adjuvant settings of solid tumors for PD-1/PD-L1 inhibitors, which could make up more than one-quarter of their sales in 2025.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel